Fig 2: Expression levels of SFMBT1 and ZHX2 in ccRCC samples. (A) Representative images of SFMBT1 and ZHX2 expression levels in ccRCC samples. Scale bar, 100 µm. (B) Relative mRNA expression levels of (B) SFMBT1 and (C) ZHX2 in fresh ccRCC tissues and adjacent normal tissues. *P<0.05. SFMBT1, scm-like with four malignant brain tumor domains; ZHX2, zinc fingers and homeoboxes 2; ccRCC, clear cell renal cell carcinoma; T, tumor; N, normal.

Fig 3: Kaplan-Meier survival analysis of patients with clear cell renal cell carcinoma, based on SFMBT1 and ZHX2 expression levels. (A) OS rate and (B) DFS rate curves based on SFMBT1 expression. (C) OS rate and (D) DFS rate curves based ZHX2 expression. SFMBT1, scm-like with four malignant brain tumor domains; ZHX2, zinc fingers and homeoboxes 2; OS, overall survival; DFS, disease-free survival.